Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months
* Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
Breast cancer patients with any receptor type
English speaking
Able to participate in the informed consent process
Women, 18 years of age and older.
Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months
* Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
Women with newly diagnosed breast cancer (stage 0-III) who have not yet started treatment and are planning to start Tamoxifen as their only form of systemic treatment within one month
Breast cancer patients with any receptor type
English speaking
Able to participate in the informed consent process
Women, 18 years of age and older.
Postmenopausal women at time of diagnosis who have been without period for ≥ 2 years.
Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
Breast cancer patients with any receptor type
English speaking
Able to participate in the informed consent process
You may not be if
Active secondary cancer requiring cytotoxic chemotherapy
Prior systemic treatment for a malignancy
Clareo Health | Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
